Trial Profile
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [¹⁴C]-Tucatinib Following a Single Oral Dose in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary)
- Indications Breast cancer; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors Cascadian Therapeutics
- 05 Dec 2018 New trial record